Searched for
HONASA CONSUMER FLUENCE PHARMA DEAL
India's growth story, not AI trade reversal, will drive foreign flows: Sameer DalalIndia's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correct...- Why Meta tapped Kunal Shah; Beauty’s new factory boomHappy Wednesday! Meta just handed WhatsApp’s steering wheel to Cred’s Kunal Shah, betting he can turn India’s favourite chat app into a pay...
- Stocks in news: Vedanta, Honasa Consumer, IRCTC, Bajaj Auto, Tata MotorsIndian markets experienced profit booking, falling over a percent amidst a weak global trend. Key stocks like Vedanta, Honasa Consumer, IRC...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Sensex rises 291 points, Nifty closes above 24,100; Tech Mahindra, Sun Pharma among top gainersIndian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Dealmaking stays strong as startup M&A momentum carries into 2026Indian startups are experiencing a surge in M&A exits, particularly in consumer, fintech, and ecommerce sectors, signalling a robust recove...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Manu Chandra's Sauce, the VC making a feast of small servingsSauce VC is set to make an estimated Rs 500-550 crore from L'Oréal's acquisition of Innovist, validating founder Manu Chandra's strategy of...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...
- US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisitionThe U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...
- Fable 5's cost challenge; Opendoor's India exitAnthropic's Fable 5 could rewrite how IT works, but the price tag and performance quirks raise hard questions. This and more in today’s ETt...
- Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a monthDespite weakness in the broader market, seven BSE 500 stocks including Honasa Consumer, Aegis Logistics and Gland Pharma scaled fresh 52-we...
- Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth ra...
Load More
